title: L-carnitine supplementation decreases the left ventricular mass in patients undergoing hemodialysis.
abstract: BACKGROUND
  Patients on long-term hemodialysis become deficient in carnitine and are frequently treated with carnitine supplementation to offset their renal anemia, lipid abnormality and cardiac dysfunction. The therapeutic value of carnitine supplementation on left ventricular hypertrophy (LVH) in patients with normal cardiac systolic function remains uncertain.
  
  
  RESULTS
  The cardiac morphology and function of 10 patients given 10 mg/kg of L-carnitine orally, immediately after hemodialysis sessions 3 times per week for a 12-month period were compared with 10 untreated control patients. Using echocardiography, left ventricular fractional shortening (LVFS) and left ventricular mass index (LVMI) were measured before and after the study period. As a result, amounts of serum-free carnitine increased from 28.4+/-4.7 to 58.5+/-12.1 micromol/L. The LVMI decreased significantly from 151.8+/-21.2 to 134.0+/-16.0 g/m(2) in treated patients (p<0.01), yet the LVMI in untreated control patients did not change significantly (ie, from 153.3+/-28.2 to 167.1+/-43.1 g/m(2)). However, LVFS values remained unchanged in both groups. Although L-carnitine promoted a 31% reduction in erythropoietin requirements, hematocrit and blood pressure did not change during the study period.
  
  
  CONCLUSIONS
  Supplementation with L-carnitine induced regression of LVH in patients on hemodialysis, even for those with normal systolic function.
authors.affiliation: Kidney Center of Shinraku-en Hospital, 3-1-1 Shindori-minami, Niigata 950-2087, Japan. t-sakura@db3.so-net.ne.jp
authors.forename: Tai
authors.initials: T
authors.lastname: Sakurabayashi
authors.forename: Shigeru
authors.initials: S
authors.lastname: Miyazaki
authors.forename: Yasuko
authors.initials: Y
authors.lastname: Yuasa
authors.forename: Shinji
authors.initials: S
authors.lastname: Sakai
authors.forename: Masashi
authors.initials: M
authors.lastname: Suzuki
authors.forename: Sachio
authors.initials: S
authors.lastname: Takahashi
authors.forename: Yoshihei
authors.initials: Y
authors.lastname: Hirasawa
mesh_terms: D000284:Administration, Oral; D000328:Adult; D001794:Blood Pressure; D001835:Body Weight; D002331:Carnitine / Q000008:administration & dosage*; D004452:Echocardiography; D005260:Female; D006400:Hematocrit; D006801:Humans; D017379:Hypertrophy, Left Ventricular / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy*; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D016896:Treatment Outcome; D014803:Vitamin B Complex / Q000008:administration & dosage*
chemical_list: D014803:Vitamin B Complex; D002331:Carnitine